Funding for this research was provided by:
JCR Pharmaceuticals Co., Ltd.
Received: 21 August 2020
Revised: 1 September 2020
Accepted: 1 September 2020
First Online: 28 September 2020
Conflict of interest
: Tomonobu Hasegawa has the following financial relationships to disclose: Research funding from Novo Nordisk Pharma Ltd. and JCR Pharmaceuticals Co., Ltd.